Almirall, Stiefel Make Dermo Product Swap
This article was originally published in Scrip
Dermatology-driven Almirall has acquired the rights to Veltin (clindamycin + tretinoin) and Altabax (retapamulin) from Stiefel, a GlaxoSmithKline plc company, in exchange for an undisclosed cash payment and distribution rights to Toctino (alitretinoin).
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.